TLDR
- ARK Invest acquired 233,482 shares of Rocket Lab valued at approximately $16.4 million on October 1.
- The investment firm offloaded 20,805 Palantir shares representing roughly $4 million in value during the same trading session.
- Additional purchases included positions in BWX Technologies, Intellia Therapeutics, and Veracyte.
- ARK reduced holdings in Alphabet and exited a minor Zillow position.
- Analysts assign Rocket Lab a Strong Buy consensus with 56% potential upside, while Palantir receives a Moderate Buy rating with 6% projected gains.
On Thursday, October 1, Cathie Wood’s ARK Invest executed multiple significant portfolio adjustments. The firm’s publicly disclosed trading activity revealed substantial investments in select companies while reducing exposure to others.
The investment manager purchased 233,482 Rocket Lab shares distributed across three separate ARK funds. This strategic acquisition totaled approximately $16.4 million in value.
Concurrently, ARK divested 20,805 Palantir shares in a transaction valued at nearly $4 million.
Year-to-date performance shows Rocket Lab shares climbing approximately 1%, while Palantir has posted gains of roughly 7% over the identical timeframe.
Rocket Lab Secures Major Commercial Contracts and Expands Operations
The aerospace company recently finalized its most substantial commercial contract to date for the Electron launch vehicle. This agreement encompasses 20 additional launches for Japan-based Synspective.
This arrangement brings Synspective’s total mission bookings with Rocket Lab to 47, providing the launch provider with enhanced revenue visibility moving forward.
Rocket Lab delivered second-quarter revenue of $234 million, representing a 62% year-over-year increase.
Development continues on the company’s Neutron launch system. Additionally, Rocket Lab is advancing its proposed acquisition of satellite communications firm Iridium Communications.
Wall Street sentiment toward Rocket Lab remains predominantly bullish. Among 16 covering analysts, 14 maintain Buy ratings while 2 recommend Hold positions.
The consensus price target stands at $110.07, implying potential upside of 56% from current trading levels.
Palantir Demonstrates Strong Revenue Acceleration in Commercial Segment
Palantir’s second-quarter revenue surged 93% year-over-year to $1.94 billion. The U.S. commercial segment experienced particularly robust growth, with revenue climbing 149% to $764 million.
During the quarter, the software company executed 220 contracts valued at $1 million or greater. This activity demonstrates sustained enterprise demand for the company’s data analytics platforms.
Strategic partnerships have expanded recently, with Palantir announcing collaborations with Nebius, PwC, and Armada.
Analyst sentiment remains constructive on Palantir, albeit with less enthusiasm than Rocket Lab. Of 22 analysts tracking the stock, 16 rate it Buy, 4 assign Hold ratings, and 2 recommend Sell.
The mean price target for Palantir sits at $201.74, representing approximately 6% upside from present valuation.
Beyond the headline transactions, ARK executed several additional portfolio moves. The firm acquired shares of BWX Technologies, a nuclear component manufacturer, totaling approximately $13.6 million.
ARK expanded its holdings in Intellia Therapeutics, a gene-editing biotechnology company, through purchases valued near $5 million.
The firm also invested over $7.3 million in Veracyte, which specializes in genomic diagnostic solutions.
Among divestments, ARK marginally reduced its Alphabet position by selling 101 shares. The firm also eliminated a modest Zillow holding worth approximately $20,000.
These transactions reflect ARK’s standard practice of publishing comprehensive daily trade disclosures for all exchange-traded funds under management.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
